You can find details about how to access information remotely in this step-by-step guide. The guide will also help if for any reason you have difficulty accessing the content you want.
Molecular Omics publishes high-quality research in the -omics sciences. We welcome scientific research based on the application of any -omics technology and we encourage multi-omics approaches to solving important chemical or biological problems. This includes combining different types of omics platforms encompassing genomics, transcriptomics, proteomics, metabolomics and other specialized areas such as glycomics and lipidomics, as well as innovative bioinformatics approaches.
What would you like to know about this journal?
Molecular Omics is a Transformative Journal, and Plan S compliant
Impact factor: 3.0*
Time to first decision (all decisions): 6.0 days**
CiteScore: 5.4****
Time to first decision (peer reviewed only): 54.0 days***
Chair: Robert Moritz
Indexed in Web of 新月直播app下载, Scopus and MEDLINE
A trusted editorial team
Our rigorous peer review process ensures transparency, fairness and balance
Open Access options
We can help you improve the visibility of your work and meet funder mandates
No cost to publish
We don't charge submission, page or colour charges - and we offer free electronic reprints
Pre-prints welcome
We accept submissions of manuscripts that have previously been posted as pre-prints
Copyright is yours
We believe the copyright of your work should always belong to you, so we only ask for a licence to publish it
A focus on community
Because the 新月直播app下载 re-invests all surplus back into the global scientific community, you can raise your profile and support international scientific progress at the same time
Journal scope
Molecular Omics publishes high-quality research from across the -omics sciences that provide significant new insight into important chemical or biological problems.
Molecular Omics articles report research that significantly increases understanding or demonstrates clear functional benefits, supported by experimental validation or a novel data analytic approach.
Topics include, but are not limited to:
- omics studies to gain mechanistic insight into biological processes – for example, determining the mode of action of a drug or the basis of a particular phenotype, such as drought tolerance
- omics studies for clinical applications with experimental validation, such as finding biomarkers for diagnostics or potential new drug targets
- omics studies looking at the sub-cellular make-up of cells – for example, the subcellular localisation of certain proteins or post-translational modifications or new imaging techniques
- studies presenting new methods and tools to support omics studies, including new spectroscopic/chromatographic techniques, chip-based/array technologies and new classification/data analysis techniques. New methods should be proven and demonstrate an advance in the field.
The following are not within the scope of Molecular Omics:
- Research based on reanalysis of public datasets without experimental validation and significant omics datasets
- Papers without significant biological justification or interpretation
- Research that is only of interest to the specialist in the area
- Papers reporting new results that could be routinely predicted
- Papers that do not show a significant improvement over known research
Meet the team
Find out who is on the editorial and advisory boards for the Molecular Omics journal.
Chair
Robert Moritz, Institute for Systems Biology, Seattle USA
Associate editor
Hyungwon Choi, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Editorial board members
Celia Berkers, Utrecht University, Netherlands
Subhra Chakraborty, National Institute of Plant Genome Research (NIPGR), New Delhi, India
Maria do Rosário Domingues, University of Aveiro, Portugal
Ling Hao, University of Maryland, USA
Benjamin Garcia, Washington University in St Louis, Missouri, USA
Nicolle Packer, Macquarie University, Sydney, Australia
Richard Unwin, University of Manchester, UK
Michael Washburn, University of Kansas Medical Center, USA
Chris Bakal, Institute of Cancer Research, UK
Anne K Bendt, National University of Singapore, Singapore
Tunahan Cakir, Gebze Technical University, Turkey
Erin Carlson, University of Minnesota, USA
James Edwards, Saint Louis University, USA
Claire Eyers, University of Liverpool, UK
Alex Georgakilas, East Carolina University, USA
Rebekah Gundry, University of Nebraska Medical Center, USA
Walter Kolch, System Biology Ireland, Dublin, Ireland
Ben Lehner, Center for Genomic Regulation, Spain
Souvik Maiti, Institute of Genomics and Integrative Biology,India
Andrej Shevchenko, Max Planck Institute for Molecular Cell Biology and Genetics, Germany
Silke Sperling, Max Planck Institute for Molecular Genetics, Berlin, Germany
Ed Tate, Imperial College London, UK
Ronghu Wu, Georgia Institute of Technology, USA
Katie Lim, Executive Editor
Hannah Fowler, Deputy Editor
Daniel Robertshaw, Development Editor
Sarah Anthony, Editorial Production Manager
Nicola Burton, Publishing Editor
Tom Cozens, Publishing Editor
Ryan Kean, Publishing Editor
Roxane Owen, Publishing Editor
Andrea Whiteside, Publishing Assistant
Sam Keltie, Publisher, Journals, ORCID
Journal specific guidelines
Post-acquisition processing of data
All image acquisition and processing tools (including their settings) should be clearly stated in the manuscript. The amount of post-acquisition processing of data should be kept to a minimum. Any type of alteration such as image processing, cropping and groupings should be clearly stated in the figure caption and the Supplementary Information (SI) (clearly describing the process of alteration). Data manipulation (for example, normalisation or handling of missing values) should be given.
Image processing changes should be applied to the entire image as well as all other images it is compared to. Processed images should still represent all the original data (with no data missing) and touch-up tools should be avoided.
All Western blot and other electrophoresis data should be supported by the underlying raw images. The image of the full gel and blot, uncropped and unprocessed, should be provided in the supplementary information on submission. All samples and controls used for a comparative analysis should be run on the same gel or blot. For each blot and gel, all positive and negative controls and molecular size markers (for example, protein ladder) should be shown (if not in the main figure at least in the Supplementary Information (SI)). Only the results of comparable experiments should be compared.
When illustrating the blot or gel result, any cropping or rearrangement of lanes within an image should be stated in the figure legend and with lane boundaries clearly delineated. Important bands should not be cropped in gels and cropped blots should retain at least six band widths above and below the band. Alterations should be kept to a minimum required for clarity.
Each blot or gel image should be appropriately labelled, with closest molecular mass markers and lanes labelled. All details must be visible, over or underexposed gels and blots are not acceptable; a grey background is highly encouraged. Authors should be able to provide raw data for all replicate experiments upon request.
Genuine and relevant signals in spectra must not be lost due to image enhancement.
Microscopy images of cells from multiple fields should not be compared but shown as single images (at least in the Supplementary Information (SI)).
Authors might be asked during peer review to provide the original unprocessed data to the editors/reviewers of the journal.
Open access publishing options
Molecular Omics is a hybrid (transformative) journal and gives authors the choice of publishing their research either via the traditional subscription-based model or instead by choosing our gold open access option. Find out more about our Transformative Journals. which are Plan S compliant.
Gold open access
For authors who want to publish their article gold open access, Molecular Omics charges an article processing charge (APC) of £2,750 (+ any applicable tax). Our APC is all-inclusive and makes your article freely available online immediately, permanently, and includes your choice of Creative Commons licence (CC BY or CC BY-NC) at no extra cost. It is not a submission charge, so you only pay if your article is accepted for publication.
Learn more about publishing open access.
Read & Publish
If your institution has a Read & Publish agreement in place with the 新月直播app下载, APCs for gold open access publishing in Molecular Omics may already be covered.
Use our to check if your institution has an open access agreement with us.
Please use your official institutional email address to submit your manuscript and check you are assigned as the corresponding author; this helps us to identify if you are eligible for Read & Publish or other APC discounts.
Traditional subscription model
Authors can also publish in Molecular Omics via the traditional subscription model without needing to pay an APC. Articles published via this route are available to institutions and individuals who subscribe to the journal. Our standard licence allows you to make the accepted manuscript of your article freely available after a 12-month embargo period. This is known as the green route to open access.
Readership information
Researchers from industry and academia interested in molecular level research in proteomics, transcriptomics and metabolomics, genomics and other omics science.
Thus the journal will appeal to a wide variety of researchers, but particularly to the folllowing.
- Chemical biologists
- Biological chemists
- Biochemists
- Molecular and structural biologists
- Drug discovery scientists
- Protein chemists
- Bio- and cheminformaticians
- Organic and analytical chemists
Subscription information
Online only 2025: £1,629 / $2,872
*2023 Journal Citation Reports (Clarivate Analytics, 2024)
**The median time from submission to first decision including manuscripts rejected without peer review from the previous calendar year
***The median time from submission to first decision for peer-reviewed manuscripts from the previous calendar year
****CiteScore™ 2023 available at
Share
Advertisement